Key facts
- Delfina’s last known valuation is $52.0M (Jan 2025).
- It has raised $24.5M; the latest was Early Stage VC ($17.0M) in Jan 2025.
- Notable investors include MassChallenge, Goodwater Capital, Harvard Innovation Launch Lab, E14 Fund, Matchstick Ventures — 21 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 21 names
- ·Watchlist + deal alerts for Delfina
- ·The full record, as it builds
Funding rounds
No funding rounds for Delfina are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Delfina
Developer of a data-driven pregnancy care platform designed to offer a personalized prenatal care system that keeps mothers and infants safe during pregnancy. The company's platform optimizes interventional workflows using machine learning models, creates personalized pregnancy care plans based on patient risk from multiple metrics, and improves provider efficiency by supporting early intervention, enabling the healthcare industry to provide equitable and cost-effective pregnancy care.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2021
- Employees
- 12
- Website
- delfina.com/
- Ownership
- Privately Held (backing)
Delfina doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Delfina shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Delfina in its N-PORT filings yet. We sweep new filings monthly.